Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P040034/S041

DuraSeal Dural Sealant System

Integra LifeSciences Corporation · Decision date Feb 27, 2026

FDA DECISIONP040034/S041

What did the FDA approve?

FDA records P040034/S041 as a supplement to PMA P040034, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Feb 27, 2026.

FDA approval order statement

Approval for the extension of shelf-life to 18 months.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Neurology
Decision date
Feb 27, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P040034/S041
Regulatory pathway
PMA supplement
Product code
NQR
Decision code
APPR
Decision date
Feb 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Sealant, dural.

Product code
NQR
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P040034/S041 received

    Application receipt date recorded by FDA.

  2. P040034/S040 · Related supplement

    DuraSeal Dural Sealant System

  3. P040034/S041 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P040034. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P040034

Product / regulatory recordCompanyPathwayDecision dateSource
Integra LifeSciences CorporationPMA supplementDec 17, 2025FDA

Explore the linked device profile

Other records with product code NQR

Product / regulatory recordCompanyPathwayDecision dateSource
Pramand, LLCPMA supplementOct 1, 2026FDA
Pramand, LLCPMA supplementSep 11, 2026FDA
Pramand, LLCPMA supplementAug 31, 2026FDA
Pramand, LLCPMA supplementAug 5, 2026FDA
Stryker Leibinger GmbH & Co. KGPMA supplementJul 15, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Integra LifeSciences Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
311 Enterprise Dr., Planisboro, NJ, 08536

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records